Biotech News
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
ir.protaratx.com2026-05-06 15:15 EST
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational